(Q35915283)

11 August 2017

1 reference

title

Rationale for new treatments aimed at IgE immunomodulation (English)

1 reference

11 August 2017

Jeffrey Stokes

1

1 reference

11 August 2017

Thomas B Casale

series ordinal

2

1 reference

11 August 2017

publication date

1 September 2004

1 reference

Annals of Allergy, Asthma & Immunology

11 August 2017

published in

1 reference

11 August 2017

volume

93

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

212-7; quiz 217-9, 271

1 reference

The role of transcription factors in allergic inflammation

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Gene expression of the GATA-3 transcription factor is increased in atopic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Signaling molecules as therapeutic targets in allergic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

The role of PPARgamma-dependent pathway in the development of cardiac hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

PPAR‐α and ‐γ but not ‐δ agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF‐κB‐independent effect

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Down-regulation of Th2 cell-mediated murine peritoneal eosinophilia by antiallergic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Suppression of IgE production by IPD-1151T (suplatast tosilate), a new dimethylsulfonium agent: (2). Regulation of human IgE response.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Effect of suplatast tosilate on airway hyperresponsiveness and inflammation in asthma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Effects of suplatast tosilate on allergic eosinophilic airway inflammation in patients with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Tokyo Joshi-Idai Asthma Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Effect of suplatast tosilate, a Th2 cytokine inhibitor, on cough variant asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

IFN-gamma and IL-12 plasmid DNAs as vaccine adjuvant in a murine model of grass allergy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Molecular and cellular mechanisms of allergic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Co-crosslinking Fc epsilon RII/CD23 and B cell surface immunoglobulin modulates B cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Critical role of CD23 in allergen-induced bronchoconstriction in a murine model of allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

CD23 exhibits negative regulatory effects on allergic sensitization and airway hyperresponsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Experiences with monoclonal antibody therapy for allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Omalizumab treatment downregulates dendritic cell FcepsilonRI expression

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Omalizumab is effective in the long-term control of severe allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Omalizumab improves asthma-related quality of life in children with allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Antiviral agents for treatment of herpes simplex virus infection in neonates

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

Effect of anti-IgE therapy in patients with peanut allergy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961490-1

7 January 2021

10.1016/S1081-1206(10)61490-1

Identifiers

DOI

1 reference

11 August 2017

1 reference